Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
President Trump's administration have reinstated a likeness of Winston Churchill to the White House's most famous room.
Data-selling companies trade personal addresses and phone numbers for as little as 4p per record, a watchdog has warned.
A bitterly cold airmass covers the UK this weekend.